Evinova, a new health-tech business launched by AstraZeneca, is set to revolutionize the way clinical trials are designed and delivered. Leveraging the company’s expertise in this area, Evinova will offer solutions at scale to trial sponsors, clinical research organizations, care teams, and patients.
The company’s offerings will include advanced data collection methods and machine learning algorithms to support teams in designing their studies. This aim to reduce the time and cost of developing new medicines, bring care closer to home for patients, and ease the burden on health systems. Evinova has announced major collaborations with Parexel and Fortrea to expand the reach of its digital health solutions to a wider customer base.
AstraZeneca’s CEO Pascal Soriot expressed confidence in Evinova’s ability to make a significant impact on patient care, healthcare transformation, and carbon emissions reduction. The company also highlighted the expected growth of the digital-health market, projecting it to be worth more than $900 billion by 2032.
For more information about Evinova and its offerings, contact Michael Susin at email@example.com